Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erratum to: Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K, Willkom M, Martin R, Chang S, Wei L, Liu H, Liu YP, Graham H, Quirk E, Martin H, White KL. Andreatta K, et al. J Antimicrob Chemother. 2019 Dec 1;74(12):3646-3647. doi: 10.1093/jac/dkz412. J Antimicrob Chemother. 2019. PMID: 31562501 Free PMC article. No abstract available.
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK, Willkom M, Andreatta K, Liu H, Martin R, Parvangada A, Martin H, Collins S, White KL. Acosta RK, et al. Among authors: andreatta k. J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):363-371. doi: 10.1097/QAI.0000000000002454. J Acquir Immune Defic Syndr. 2020. PMID: 32701823 Clinical Trial.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
D'Antoni ML, Andreatta K, Acosta R, Martin H, Chang S, Martin R, White KL. D'Antoni ML, et al. Among authors: andreatta k. J Acquir Immune Defic Syndr. 2022 Apr 1;89(4):433-440. doi: 10.1097/QAI.0000000000002888. J Acquir Immune Defic Syndr. 2022. PMID: 34897227 Free PMC article. Clinical Trial.
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Sax PE, Andreatta K, Molina JM, Daar ES, Hagins D, Acosta R, D'Antoni ML, Chang S, Martin R, Liu H, Blair C, McNicholl I, Gallant J, Collins SE, Martin H, White KL. Sax PE, et al. Among authors: andreatta k. AIDS. 2022 Sep 1;36(11):1511-1520. doi: 10.1097/QAD.0000000000003244. Epub 2022 Apr 23. AIDS. 2022. PMID: 35466963 Free PMC article.
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E. Daar ES, et al. Among authors: andreatta k. Lancet HIV. 2018 Jul;5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2. Epub 2018 Jun 18. Lancet HIV. 2018. PMID: 29925490 Clinical Trial.
23 results